Literature DB >> 19485735

Combined surgical/endovascular treatment of a complex dural arteriovenous fistula in 21-month-old. Technical note.

R Webster Crowley1, Avery J Evans, Mary E Jensen, Neal F Kassell, Aaron S Dumont.   

Abstract

The treatment of intracranial dural arteriovenous fistulas (AVF) has progressed considerably over the past few decades. With the introduction of new embolic materials and refinement of endovascular techniques, lesions that in the past may have required extensive surgery, or were considered untreatable, have increasingly become curable. Despite improvements in technology, not every condition is amenable to an endovascular treatment, including those patients with preexisting vascular abnormalities that preclude an endovascular approach. In these cases, the patient may be left with suboptimal treatment options with higher associated risks. The authors here report on the treatment of a dural AVF in a pediatric patient in whom prior procedures rendered his cerebrovascular anatomy unnavigable using traditional endovascular techniques. To circumvent these vascular abnormalities the patient underwent combined surgical/endovascular treatment that included surgical exposure and cannulation of the cervical carotid artery, as well as simultaneous femoral artery access, with subsequent successful transarterial embolization of the dural AVF.

Entities:  

Mesh:

Year:  2009        PMID: 19485735     DOI: 10.3171/2009.2.PEDS08469

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  2 in total

1.  Direct access to the middle meningeal artery for embolization of complex dural arteriovenous fistula: a hybrid treatment approach.

Authors:  Ning Lin; Adam M Brouillard; Maxim Mokin; Sabareesh K Natarajan; Kenneth V Snyder; Elad I Levy; Adnan H Siddiqui
Journal:  BMJ Case Rep       Date:  2014-06-05

Review 2.  Therapeutic progress in pediatric intracranial dural arteriovenous shunts: A review.

Authors:  Jinlu Yu; Xianli Lv; Youxiang Li; Zhongxue Wu
Journal:  Interv Neuroradiol       Date:  2016-06-15       Impact factor: 1.610

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.